Press Releases Year None20212020201920182017 June 3, 2019 SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1 PDF Version May 20, 2019 SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors PDF Version May 6, 2019 SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors PDF Version April 1, 2019 SpringWorks Therapeutics Completes $125 Million Series B Financing PDF Version March 4, 2019 SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference PDF Version December 20, 2018 SpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PDF Version November 7, 2018 SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors PDF Version November 5, 2018 SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1 PDF Version September 6, 2018 BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors PDF Version September 5, 2018 SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer PDF Version Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Next page next › Last page last »
June 3, 2019 SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1 PDF Version
May 20, 2019 SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors PDF Version
May 6, 2019 SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors PDF Version
March 4, 2019 SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference PDF Version
December 20, 2018 SpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PDF Version
November 7, 2018 SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors PDF Version
November 5, 2018 SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1 PDF Version
September 6, 2018 BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors PDF Version
September 5, 2018 SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer PDF Version
